The purpose of this study is to understand real world gefitinib usage patterns, patient characteristics and outcomes and to present these for a Caucasian population

A multicentre, retrospective chart review study to characterise gefitinib usage and outcomes in routine treatment

Inclusion Criteria:

• Patients who received gefitinib first line in the UK Single Payment Access (SPA) scheme
• Locally advanced or metastatic EGFR mutation positive NSCLC
• Supplied with first pack of gefitinib prior to 1st January 2012

Exclusion Criteria:

• Patient was treated privately (i.e. outside the NHS)
• Gefitinib was second-line therapy following treatment failure on a prior therapy

hospital clinic